Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/1338042/000110465916137804/a16-16151_1ex99d1.htm
November 2016
November 2016
November 2016
October 2016
October 2016
October 2016
August 2016
July 2016
Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/1338042/000110465916137804/a16-16151_1ex99d1.htm
Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Aegerion Pharmaceuticals, Inc..
Aegerion Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2016 10-K Annual Report includes:
Ticker: AEGREvents:
CIK: 1338042
Form Type: 8-K Corporate News
Accession Number: 0001104659-16-137804
Submitted to the SEC: Mon Aug 08 2016 11:00:31 AM EST
Accepted by the SEC: Mon Aug 08 2016
Period: Monday, August 8, 2016
Industry: Pharmaceutical Preparations